Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

In addition, the company reported a 21% mean weight loss in a higher dose cohort of the 7.2 mg formulation of Wegovy (semaglutide) in the Phase 3b STEP UP trial. Amycretin functio ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Data on the subcutaneous version of amycretin is due next year, and Novo Nordisk also presented early data on another oral therapy, CBR1 inverse agonist monlunabant (INV-202), which showed a 3% ...

PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to ...

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity and who are overweight. Following a positive end-of-Phase II meeting ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company ...

Amycretin led to 22% weight loss at the highest dose, while placebo groups gained weight. Novo Nordisk stock is down 5.5% YTD and 43% over the past year. Get daily-updated rankings across momentum ...

Bagsværd, Denmark, 12 June 2025– Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical studies.